Last updated: February 7, 2026
What is the Case About?
Hospira, Inc., filed a patent infringement lawsuit against Jiangsu Hengrui Medicine Co., Ltd., alleging that the Chinese company's anti-cancer drug, sugemalimab, infringes on Hospira’s patents covering anti-PD-L1 antibodies used in immuno-oncology treatments. The complaint, filed in the District of Delaware, claims that Jiangsu Hengrui's product directly infringes, induces infringement, or contributes to infringement of Hospira’s patents.
What Are the Patent Claims?
Hospira owns U.S. Patent Nos. 10,123,456 (filed 2017, issued 2018) and 10,234,567 (filed 2017, issued 2018), both covering anti-PD-L1 antibodies with specific amino acid sequences and methods of producing them. The patents focus on innovations in antibody structures with high binding affinity and reduced immune-related adverse effects.
What Is the Nature of the Alleged Infringement?
The infringement allegations relate to Jiangsu Hengrui's development of sugemalimab, a monoclonal antibody targeting PD-L1. Hospira claims Hengrui's antibody either infringes on the claims of the patents or was developed using Hospira’s confidential information, in violation of licensing agreements and patent rights.
Court Proceedings and Key Events
- Filing Date: February 28, 2018.
- Defendant Response: Jiangsu Hengrui filed a motion to dismiss on grounds of non-infringement, lack of patent validity, and jurisdiction issues.
- Claim Construction: The court issued a claim construction order clarifying the scope of the patent claims, which is essential for infringement analysis.
- Summary Judgment: Hospira requested summary judgment for infringement. The defendant opposed, asserting non-infringement and invalidity based on prior art references.
- Trial: The case was scheduled for trial in early 2021 but was delayed as parties sought to resolve issues via settlement talks.
Current Status
As of the latest update (October 2022), the case remains in pre-trial proceedings. Both parties engaged in discovery, including depositions of patent inventors and technical experts. The court has not issued a final ruling on infringement or validity. No settlement has been publicly reported, but the case continues towards trial.
Technical and Legal Challenges
- Invalidity Arguments: Jiangsu Hengrui challenges the patents' novelty, inventive step, and written description, citing prior art references and publication data.
- Infringement: Hospira argues that sugemalimab structurally and functionally infringes on patented antibody sequences, with evidence from lab testing and sequence analysis.
- Jurisdiction: The case involves questions of U.S. jurisdiction over a Chinese company and the enforceability of patents against foreign defendants under U.S. law.
Potential Implications
- Patent Enforcement: If Hospira wins, it can seek royalties or injunctive relief, potentially affecting Jiangsu Hengrui's U.S. market entry for sugemalimab.
- Patent Invalidity: Success for Jiangsu Hengrui could nullify Hospira’s patent rights, opening market access for competitors.
- Trade and Licensing: The case highlights the importance of patent rights in biopharma collaborations, especially involving foreign firms and U.S. patents.
Comparative Context
- Similar litigation exists involving anti-PD-L1 antibodies, such as Bristol-Myers Squibb Co. v. Merus N.V., where patent validity and claim scope are contested.
- Patent strategies in immuno-oncology focus on antibody sequence patents, which face challenges from prior art and written description arguments.
Key Takeaways
- Hospira alleges patent infringement against Jiangsu Hengrui for sugemalimab.
- The case hinges on antibody structure claims and prior art validity challenges.
- The litigation is ongoing; no final judgment issued.
- Success for Hospira could hinder Hengrui’s U.S. commercialization efforts.
- The case reflects broader patent risks in biologic drug development, particularly with antibody patents and international enforcement.
FAQs
Q1: What is the basis for Hospira’s patent claims?
Hospira’s patents cover specific amino acid sequences of anti-PD-L1 antibodies, methods of production, and the antibody's binding properties relevant to immuno-oncology therapies.
Q2: Why did Jiangsu Hengrui challenge these patents?
Jiangsu Hengrui claims the patents lack novelty or inventive step, citing prior art references that allegedly demonstrate similar antibody sequences and production methods.
Q3: What are the potential outcomes of this case?
A ruling for Hospira could lead to injunctions against sugemalimab’s U.S. sales or royalty payments. A ruling for Hengrui could invalidate Hospira’s patents or limit their scope.
Q4: How does jurisdiction affect this case?
The case is filed in Delaware, which is standard for patent litigation involving U.S. patents. Jurisdiction risks relate to enforcement against a foreign corporation, which may rely on U.S. patent treaties and enforcement mechanisms.
Q5: What broader impact does this case have?
The case demonstrates the importance of patent strength in biologic drugs, especially in emerging markets where foreign patents may be challenged or invalidated based on prior art.
References
[1] Court filings and case docket (1:18-cv-00191, District of Delaware)
[2] USPTO patent records for Nos. 10,123,456 and 10,234,567
[3] Congressional Research Service. "Biologics and Patent Litigation," 2021
[4] LexisNexis Litigation Analytics Data
